[The treatment of brucellosis using rifampicine (author's transl)].
The authors discuss the present value of rifampicin in the treatment of human brucellosis on the basis of: 1) a bacteriological study of 42 strains of Brucella spp. (MIC's of rifampicin, tetracyclin, doxycyclin, minocyclin and streptomycin; results of doxycyclin-rifampicin and doxycyclin-streptomycin combinations), and 2) a clinical study of 38 cases of brucellosis treated with rifampicin, including 25 acute septicemias and 13 osteo-arthritis. Satisfactory results were observed in 92% of the cases with rifampicin alone, but one cannot state that the benefits are significant.
D000208:Acute Disease; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002002:Brucella / Q000187:drug effects; D002006:Brucellosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy / Q000209:etiology; D011247:Pregnancy; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D012293:Rifampin
Traitement de la brucellose par la rifampicine. Résultats préliminaires.